BR112016013974A2 - Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto - Google Patents

Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto

Info

Publication number
BR112016013974A2
BR112016013974A2 BR112016013974A BR112016013974A BR112016013974A2 BR 112016013974 A2 BR112016013974 A2 BR 112016013974A2 BR 112016013974 A BR112016013974 A BR 112016013974A BR 112016013974 A BR112016013974 A BR 112016013974A BR 112016013974 A2 BR112016013974 A2 BR 112016013974A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
compounds
present
relates
Prior art date
Application number
BR112016013974A
Other languages
English (en)
Other versions
BR112016013974B1 (pt
BR112016013974A8 (pt
Inventor
Nirogi Ramakrishna
Rasheed Mohammed Abdul
Karbhari Shinde Anil
Reddy Gagginapally Shankar
Jasti Venkateswarlu
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BR112016013974A2 publication Critical patent/BR112016013974A2/pt
Publication of BR112016013974A8 publication Critical patent/BR112016013974A8/pt
Publication of BR112016013974B1 publication Critical patent/BR112016013974B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, USO DA COMPOSIÇÃO FARMACÊUTICA E USO DO COMPOSTO. A presente invenção se refere a novos compostos indazola tendo a fórmula (I), que incluem os seus estereoisômeros e os seus sais farmaceuticamente aceitáveis. A presente invenção também se refere a métodos de produzir os referidos compostos e composições farmacêuticas que compreendem os referidos compostos. Os compostos da presente invenção são úteis no tratamento de várias desordens que são relacionadas aos agonistas receptores de 5-hidroxitriptamina 4 (5-HT4).
BR112016013974-7A 2013-12-16 2014-02-24 Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto BR112016013974B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN5852/CHE/2013 2013-12-16
IN5852CH2013 2013-12-16
PCT/IN2014/000116 WO2015092804A1 (en) 2013-12-16 2014-02-24 Indazole compounds as 5-ht4 receptor agonists

Publications (3)

Publication Number Publication Date
BR112016013974A2 true BR112016013974A2 (pt) 2017-08-08
BR112016013974A8 BR112016013974A8 (pt) 2018-01-30
BR112016013974B1 BR112016013974B1 (pt) 2022-11-22

Family

ID=50736125

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013974-7A BR112016013974B1 (pt) 2013-12-16 2014-02-24 Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto

Country Status (17)

Country Link
US (1) US9951045B2 (pt)
EP (1) EP3099675B1 (pt)
JP (1) JP6161823B2 (pt)
KR (1) KR101824154B1 (pt)
CN (1) CN105873920B (pt)
AP (1) AP2016009253A0 (pt)
AU (1) AU2014369085B2 (pt)
BR (1) BR112016013974B1 (pt)
CA (1) CA2932428C (pt)
DK (1) DK3099675T3 (pt)
EA (1) EA029951B1 (pt)
ES (1) ES2668873T3 (pt)
IL (1) IL245948B (pt)
MX (1) MX368017B (pt)
NZ (1) NZ720879A (pt)
SG (1) SG11201604849YA (pt)
WO (1) WO2015092804A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819286T3 (es) 2014-08-16 2021-04-15 Suven Life Sciences Ltd Proceso para la producción a gran escala de oxalato de 1—isopropil—3—{5—[1—(3—metoxipropil) piperidin—4—il]— [1,3,4]oxadiazol—2—il}—1H—indazol
RS59066B1 (sr) 2015-02-13 2019-09-30 Suven Life Sciences Ltd Jedinjenja amida kao agonisti 5-ht4 receptora
JP6900028B2 (ja) * 2017-03-29 2021-07-07 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤
EP3628660A1 (en) * 2018-09-28 2020-04-01 Université de Caen Normandie Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases
EP4317141A1 (en) 2022-08-04 2024-02-07 Curia Spain S.A.U. Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708174A (en) 1992-03-12 1998-01-13 Smithkline Beecham P.L.C. Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
WO1994010174A1 (en) 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
JP2005526003A (ja) 2001-10-22 2005-09-02 ファイザー株式会社 ５−ｈｔ４受容体調節剤としてのイミダゾピリジン化合物
CA2523077A1 (en) 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
CA2545092C (en) 2003-11-24 2010-08-17 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
CA2551171C (en) * 2003-12-23 2012-07-10 Bio-Medisinsk Innovasjon As Modulators of peripheral 5-ht receptors
NZ555180A (en) * 2004-12-22 2010-09-30 Theravance Inc Indazole-carboxamide compounds useful as 5-HT4 receptor agonists
DK1856114T3 (en) 2005-02-25 2014-11-17 Raqualia Pharma Inc Benzisoxazol-DERIVATIVES
US7906532B2 (en) 2005-07-22 2011-03-15 Pfizer Inc. Indazole derivatives
WO2011099305A1 (en) 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
US9079894B2 (en) * 2011-09-19 2015-07-14 Suven Life Sciences Ltd Heteroaryl compounds as 5-HT4 receptor ligands

Also Published As

Publication number Publication date
DK3099675T3 (en) 2018-05-22
CA2932428A1 (en) 2015-06-25
MX368017B (es) 2019-09-13
SG11201604849YA (en) 2016-07-28
CN105873920B (zh) 2018-06-08
KR20160075832A (ko) 2016-06-29
IL245948B (en) 2019-08-29
AU2014369085B2 (en) 2017-02-23
NZ720879A (en) 2017-05-26
AU2014369085A1 (en) 2016-06-30
EA029951B1 (ru) 2018-06-29
BR112016013974B1 (pt) 2022-11-22
CN105873920A (zh) 2016-08-17
AP2016009253A0 (en) 2016-06-30
US20160311797A1 (en) 2016-10-27
ES2668873T3 (es) 2018-05-22
JP2016540796A (ja) 2016-12-28
WO2015092804A1 (en) 2015-06-25
JP6161823B2 (ja) 2017-07-12
EP3099675A1 (en) 2016-12-07
EA201691252A1 (ru) 2016-12-30
EP3099675B1 (en) 2018-02-14
KR101824154B1 (ko) 2018-03-14
CA2932428C (en) 2017-10-24
IL245948A0 (en) 2016-08-02
MX2016007857A (es) 2016-09-07
US9951045B2 (en) 2018-04-24
BR112016013974A8 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
BR112016016844A2 (pt) Compostos heterocíclicos
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
EA201591195A1 (ru) Новые хинолоновые производные
EA201690888A1 (ru) Новые гетероциклические соединения
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
PH12016500985A1 (en) Use of benzimidazole-proline derivatives
BR112017017275A2 (pt) composto, composição farmacêutica, método para o tratamento e uso do composto
BR112016013974A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
PH12016500980B1 (en) Amide derivatives for gpr119 agonist
BR112015024060A2 (pt) composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
BR112017012965A2 (pt) derivados de fumagilol
EA201600032A1 (ru) Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
EA202091302A1 (ru) Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2014, OBSERVADAS AS CONDICOES LEGAIS